• English
    • Persian
    • English
    • Persian
  • Persian 
    • English
    • Persian
    • English
    • Persian
  • ورود
مشاهده آیتم 
  •   صفحه اصلی مخزن دانش
  • TBZMED Published Academics Works
  • Published Articles
  • مشاهده آیتم
  •   صفحه اصلی مخزن دانش
  • TBZMED Published Academics Works
  • Published Articles
  • مشاهده آیتم
JavaScript is disabled for your browser. Some features of this site may not work without it.

PPAR-gamma in overcoming kinase resistance in chronic myeloid leukemia.

Thumbnail
تاریخ
2016
نویسنده
Yousefi, B
Shafiei-Irannejad, V
Azimi, A
Samadi, N
Zarghami, N
Metadata
نمایش پرونده کامل آیتم
چکیده
Peroxisome proliferator-activated receptor gamma (PPAR?) plays key roles in regulating cellular differentiation, proliferation and apoptosis pathways. As such, they are considered promising targets for anticancer drug development, especially for breast cancer, multiple myeloma and hematologic malignancies. Chronic myeloid leukemia (CML) is a myeloproliferative disorder arising from an oncogenic Bcr-Abl tyrosine kinase. Inhibitors of this oncogene by small molecules such as imatinib are effective only in 75% of the patient's population. One of the potential strategies to overcome this resistance is to devise combination therapy protocols with other therapeutic agents including PPAR ligands. Since PPAR ligands are potentially interesting in different hematologic malignancies, this article will review the potential of PPAR ligands for use in CML treatment.
URI
http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/39720
Collections
  • Published Articles

مخزن دانش دانشگاه علوم پزشکی تبریز در نرم افزار دی اسپیس، کپی رایت 2018 ©  
تماس با ما | Send Feedback
Theme by 
Atmire NV
 

 

مرور

همه مخزنجامعه ها و مجموعه هابراساس تاریخ انتشارنویسنده هاعنوانهاموضوعاین مجموعهبراساس تاریخ انتشارنویسنده هاعنوانهاموضوع

حساب من

ورودثبت نام

مخزن دانش دانشگاه علوم پزشکی تبریز در نرم افزار دی اسپیس، کپی رایت 2018 ©  
تماس با ما | Send Feedback
Theme by 
Atmire NV